GM-CSF

YARDLEY, Pa., August 24, 2026 Savara Inc. will present new and previously reported Phase 3 IMPALA-2 clinical trial data...

LANGHORNE, Pa., July 30, 2026 Savara Inc. announced that the European Patent Office (EPO) and the Australian Patent Office...

LANGHORNE, Pa., November 2, 2025 — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases,...